APG101
APG101 is a drug for the treatment of glioblastoma multiforme ( GBM).
Description
APG101 is a soluble, fully human CD95 -Fc fusion protein for the treatment of malignant diseases. APG101 consists of the extracellular domain of the CD95 receptor and the Fc portion of the antibody IgG. APG101 prevents the binding of the CD95 ligand ( CD95L ) on the CD95 - receptor ( CD95). So far APG101 was tested on 20 healthy volunteers and 32 patients; it was well tolerated with no serious side effects.
The effectiveness of APG101 was investigated in a randomized clinical trial of Phase II in patients who are suffering from glioblastoma, in which a relapse of the disease occurred. Treatment consisted of either the sole Rebestrahlung the tumor region or from the Rebestrahlung with the additional gift of APG101. The recruitment of the study began in early 2010 and in February 2012 the last patient of the study had been followed up for 6 months. A total of 83 patients were treated in the clinical trial. Was apogenix According to a press release of 8 March 2012, the company, the primary endpoint of the study, a doubling of progression- free survival at 6 months, significantly exceeded. Other secondary endpoints such as overall survival or quality of life data will be reported.
With APG101 an approach pursued so far for the treatment of glioblastoma, as it is a therapeutic target to prevent the invasive growth of glioblastoma cells. This therapy is based on findings from the German Cancer Research Center, which in glioblastoma cells stimulates the binding of CD95 ligand to the CD95 receptor, the invasive growth of tumor cells. Therefore, a blockade of this binding by APG101 leads to the prevention of invasive growth of these cells.
The 27 May 2010 published in the journal "Nature" article " CD95 Promotes Tumour growth" supports applied at APG101 principle of blocking the C95/CD95L-Systems in the therapy of tumors. The essay was submitted by Peter Marcus at the University of Chicago.
APG101 received in 2009 in Europe and the U.S. Orphan Drug Status.